Lornoxicam Versus Etodolac After Third Molar Surgery

Comparison of Lornoxicam and Etodolac on Edema, Trismus and Pain After Third Molar Surgery

Our study aimed to compare the effect of lornoxicam and etodolac on postoperative pain, edema and trismus following lower third molar extraction

Study Overview

• Status: Completed
• Conditions: Edema; Pain, Acute; Trismus
• Intervention / Treatment: Drug: Lornoxicam 8 Mg Oral Tablet

Detailed Description

20 patients included in study (4 male, 16 female). Lornoxicam and etodolac was given following lower third molar extraction. Pain was evaluated 2., 6., 12., 24., and 48. hours using VAS. Edema was evaluated by measuring tragus-labial commissure, angulus- lateral canthus of eye and angulus mandible-labial commissure. Trismus was evaluated measuring mouth opening by caliper. Edema and Trismus was evaluated by 48. and 168. hours

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Phase 4

Contacts and Locations

Study Locations

• Turkey
  • Kutahya, Turkey, 43000
    • Zülfikar Karabıyık

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 30 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Bilateral mesioangular impacted lower third molar
• Asymptomatic Third Molar (No history of infection)
• Systemically Healthy Person
• Person Between aged 18-30

Exclusion Criteria:

• People who are pregnant and lactation process
• People who had any systemic disease
• People who are gastrointestinal problems
• People who are sensitive to drugs used in study
• Lower Third Molar associated with cysts and infections

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Etodolac; Etodolac, 400 mg tid per a day for four days	Drug: Lornoxicam 8 Mg Oral Tablet; Lornoxicam is a oxicam grup non-steroid antiinflamatuar drug; Other Names: Etodolac
Active Comparator: Lornoxicam; Lornoxicam, 8 mg twice per day for four days	Drug: Lornoxicam 8 Mg Oral Tablet; Lornoxicam is a oxicam grup non-steroid antiinflamatuar drug; Other Names: Etodolac

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pain after wisdom tooth extraction	Pain after lower third molar removal, Pain was evaluated with VAS(visual anolog scale)	2 th hours
Edema after wisdom tooth extraction	Edema lower third molar removal, Edema was evaluated by using reference line on the face	48 th hours
Trismus after wisdom tooth extraction	Trismus lower third molar removal, trismus was evaluated by using caliper	48 th hours,

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pain after wisdom tooth extraction	Pain after lower third molar removal, Pain was evaluated with VAS(visual anolog scale)	6 th hours
Pain after wisdom tooth extraction	Pain after lower third molar removal, Pain was evaluated with VAS(visual anolog scale)	12 th hours
Pain after wisdom tooth extraction	Pain after lower third molar removal, Pain was evaluated with VAS(visual anolog scale)	24 th hours
Pain after wisdom tooth extraction	Pain after lower third molar removal, Pain was evaluated with VAS(visual anolog scale)	48 th hours
Edema after wisdom tooth extraction	Edema lower third molar removal, Edema was evaluated by using reference line on the face	168 th hours
Trismus after wisdom tooth extraction	Trismus lower third molar removal, trismus was evaluated by using caliper	168 th hours

Collaborators and Investigators

• Sponsor: Kutahya Health Sciences University

Study record dates

Study Major Dates

• Study Start (Actual): July 20, 2022
• Primary Completion (Actual): September 25, 2022
• Study Completion (Actual): September 29, 2022

Study Registration Dates

• First Submitted: October 31, 2022
• First Submitted That Met QC Criteria: December 23, 2022
• First Posted (Estimate): January 11, 2023

Study Record Updates

• Last Update Posted (Estimate): January 11, 2023
• Last Update Submitted That Met QC Criteria: December 23, 2022
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Pain; Neurologic Manifestations; Neuromuscular Manifestations; Spasm; Acute Pain; Trismus; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Cyclooxygenase Inhibitors; Cyclooxygenase 2 Inhibitors; Etodolac; Lornoxicam
• Other Study ID Numbers: 10

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No